Rectal cancer
Conditions
Interventions
Case series:Intratumoral injection of methotrexate-packaging microparticles
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Potential patients with stage IV sigmoid-rectal cancer diagnosed by pathology or cytology or clinical examination; 2. Potential patients who failed or relapsed under the standard treatment regimen or who refused the standard treatment for their own reasons; 3. Stable vital signs, Karnofsky = 60 points; 4. Patients aged 18 to 70 years; 5. Prothrombin function is generally normal (prothrombin international standardized ratio 4.0 × 10^9/L, PLT > 80 × 10^9/L; liver function: ALT and AST = 2 times ALT/AST normal value upper limit; kidney function: BUN and Cr = 1.5 times normal upper limit (ULN) or creatinine clearance = 60 mL/min; 6. Patients or family members agree to join the group and sign informed consent form.
Exclusion criteria
Exclusion criteria: Patients can not enter or continue research if they have one of the following conditions: 1. Women who are breastfeeding, pregnant or preparing for pregnancy; 2. Patients with allergic constitution and drug allergy; 3. Potential patients with severe primary diseases such as cardio-cerebrovascular, liver, kidney, hematopoietic system and psychiatric disorders; 4. Patients with severe infection; 5. Participants of other clinical trials within the past four weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging evaluation of changes in lesion diameter;Tumor markers; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Survival period; | — |
Countries
China
Contacts
Public ContactQiu Zhao
Zhongnan Hospital of Wuhan University
Outcome results
None listed